natgillin/translations-raw huggingface dataset:
Studiet blev afblindet efter anbefaling fra datamonitoreringskomitéen efter overskridelse af tærsklen for en forud planlagt interimanalyse af PFS.
The study was unblinded upon the recommendations of the data monitoring committee after surpassing the threshold for a preplanned interim analysis of PFS. After unblinding, patients in the placebo arm were allowed to cross over to receive lenalidomide before disease progression.
Medianen for progressionsfri overlevelse var 48,1 uger (95 % konfideninterval: 36,4; 62,1) hos de patienter, der fik behandling med len/dex, mens den var på 20,0 uger (95 % konfidensinterval: 16,1; 20,1) i placebo/dex-patientgruppen.
The median progression free survival was 48.1 weeks (95% CI: 36.4, 62.1) in patients treated with len/dex versus 20.0 weeks (95% CI: 16.1, 20.1) in patients treated with placebo/dex.
Samlet overlevelse (måneder) Mediana OS-tid, måneder (95 % CI)b
Overall survival (months) Mediana OS time, months (95% CI)b
- kapselindhold: lactose, mikrokrystallinsk cellulose, croscarmellosenatrium, silica, kolloid vandfri, og magnesiumstearat
- capsule contents: lactose, microcrystalline cellulose, croscarmellose sodium, colloidal anhydrous silica, magnesium stearate.
Dosisniveau -2 5 mg dag 1-21 i 28 dages cyklus
5 mg (days 1-21 every 28 days)
• Patientkort
• Patient cards
Gastrointestinal blødning (herunder rektalblødning, hæmorideblødning, blødende mavesår og gingivalblødning)^, mundtørhed, stomatitis, dysfagi
Gastrointestinal haemorrhage (including rectal haemorrhage, haemorrhoidal haemorrhage, peptic ulcer haemorrhage and gingival bleeding)^, Dry mouth, Stomatitis, Dysphagia
Lenalidomide Accord 7,5 mg, Lenalidomide Accord 20 mg og Lenalidomide Accord 25 mg hårde kapsler
Lenalidomide Accord 7.5 mg, Lenalidomide Accord 20 mg and Lenalidomide Accord 25 mg hard capsules
Lenalidomide Accord 20 mg hårde kapsler Hver hård kapsel indeholder 20 mg lenalidomid.
Lenalidomide Accord 20 mg hard capsules Each hard capsule contains 20 mg of lenalidomide.
Sættet med oplysningsmateriale til sundhedspersonale
The Educational Healthcare Professional's Kit
Nydiagnosticeret myelomatose Vedligeholdelsesbehandling med lenalidomid hos patienter, der har gennemgået ASCT
Newly diagnosed multiple myelomaLenalidomide maintenance in patients who have undergone ASCT
Kvinder i den fertile alder skal benytte en effektiv præventionsmetode i 4 uger før behandlingen, under behandlingen, og indtil 4 uger efter lenalidomid-behandlingen.
• you must use effective methods of contraception for 4 weeks before starting treatment, during treatment, and until 4 weeks after stopping treatment.
HR [95 % CI], p-værdi MPR+R vs. MPp+p MPR+R vs. MPR+p MPR+p vs. MPp+p PFS2 (måneder) ¤ Mediana PFS2-tid, måneder (95 % CI)
MPR+R vs MPp+p MPR+R vs MPR+p MPR+p vs MPp +p PFS2 (months) ¤ Mediana PFS2 time, months (95% CI)
I IFM 2005-02-studiet var de bivirkninger, der blev observeret hyppigere med lenalidomidvedligeholdelsesbehandling end med placebo, neutropeni (60,8 %), bronkitis (47,4 %), diarré (38,9 %), nasofaryngitis (34,8 %), muskelspasmer (33,4 %), leukopeni (31,7 %), asteni (29,7 %), hoste (27,3 %), trombocytopeni (23,5 %), gastroenteritis (22,5 %) og pyreksi (20,5 %).
In the IFM 2005-02 study, the adverse reactions observed more frequently with lenalidomide maintenance than placebo were neutropenia (60.8%), bronchitis (47.4%), diarrhoea (38.9%), nasopharyngitis (34.8%), muscle spasms (33.4%), leucopenia (31.7%), asthenia (29.7%), cough (27.3%), thrombocytopenia (23.5%), gastroenteritis (22.5%) and pyrexia (20.5%).
De bivirkninger, der hyppigere blev observeret med MPR+R eller MPR+ p end med MPp+p var: neutropeni (83,3 %), anæmi (70,7 %), trombocytopeni (70,0 %), leukopeni (38,8 %), forstoppelse (34,0 %), diarré (33,3 %), udslæt (28,9 %), pyreksi (27,0 %), perifert ødem (25,0 %), hoste (24,0 %), nedsat appetit (23,7 %) og asteni (22,0 %).
The adverse reactions observed more frequently with MPR+R or MPR+p than MPp+p were: neutropenia (83.3%), anaemia (70.7%), thrombocytopenia (70.0%), leukopenia (38.8%), constipation (34.0%), diarrhoea (33.3%), rash (28.9%), pyrexia (27.0%), peripheral oedema (25.0%), cough (24.0%), decreased appetite (23.7%), and asthenia (22.0%).
Vedligeholdelsesbehandling med lenalidomid efter ASCT er forbundet med en højere forekomst af grad 4 neutropeni sammenlignet med placebo-vedligeholdelsesbehandling (32,1 % vs 26,7 % [16,1% vs 1,8% efter påbegyndelse af vedligeholdelsesbehandling] i CALGB 100104 og 16,4 % vs 0,7 % i IFM 2005-02).
Lenalidomide maintenance after ASCT is associated with a higher frequency of grade 4 neutropenia compared to placebo maintenance (32.1% vs 26.7% [16.1% vs 1.8% after the start of maintenance treatment] in CALGB 100104 and 16.4% vs 0.7% in IFM 2005-02, respectively).
• Hiven efter vejret, åndenød eller tør hoste − disse symptomer kan skyldes betændelse i lungevævet.
• Wheezing, breathlessness or a dry cough, which may be symptoms caused by inflammation of the tissue in the lungs.
Samlet overlevelse Mediana OS-tid, måneder (95% CI)b
Overall survival Mediana OS time, months (95% CI)b
Kombinationen af lenalidomid og lavdosis dexamethason hos nydiagnosticerede patienter med myelomatose er forbundet med en lavere hyppighed af grad 4 neutropeni (8,5 % med Rd og Rd18, sammenlignet med 15 % med MPT).
The combination of lenalidomide with low dose dexamethasone in newly diagnosed multiple myeloma patients is associated with a lower frequency of grade 4 neutropenia (8.5% in Rd and Rd18, compared with MPT (15%).
For hvert efterfølgende fald til under < 0,5 x 109/l
For each subsequent drop below < 0.5 x 109/L
• Nødvendigheden af omgående at oplyse det til lægen, hvis der er mistanke om graviditet
• The need to contact their doctor immediately upon suspicion of pregnancy Brochure for male patients
HR [95 % CI]c, p-værdid
HR [95% CI], p-value a
• Myelomatose hos patienter, der har fået mindst én tidligere behandling Kombination af lenalidomid sammen med dexamethason hos patienter med myelomatose med mindst én tidligere behandling er forbundet med en højere forekomst af grad 4-neutropeni (5,1 % hos patienter, som blev behandlet med lenalidomid/dexamethason, sammenlignet med 0,6 % hos patienter, som blev behandlet med placebo/dexamethason, se pkt.
• Multiple myeloma: patients with at least one prior therapy The combination of lenalidomide with dexamethasone in multiple myeloma patients with at least one prior therapy is associated with a higher incidence of grade 4 neutropenia (5.1% in lenalidomide/dexamethasone-treated patients compared with 0.6% in placebo/dexamethasone-treated patients; see section 4.8).
De bivirkninger, der hyppigere blev observeret med Rd eller Rd18 end med MPT, var: diarré (45,5 %), træthed (32,8 %), rygsmerter (32,0 %), asteni (28,2 %), insomni (27,6 %), udslæt (24,3 %), nedsat appetit (23,1 %), hoste (22,7 %), pyreksi (21,4 %) og muskelspasmer (20,5 %).
The adverse reactions observed more frequently with Rd or Rd18 than MPT were: diarrhoea (45.5%), fatigue (32.8%), back pain (32.0%), asthenia (28.2%), insomnia (27.6%), rash (24.3%), decreased appetite (23.1%), cough (22.7%), pyrexia (21.4%), and muscle spasms (20.5%).
Patienter randomiseret til armen med lenalidomid/Lavdosis dexamethason fik lenalidomid 25 mg/dag, dag 1 til 21, cyklus på 28 dage plus lavdosis dexamethason - 40 mg/dag på dag 1, 8, 15 og 22, cyklus på 28 dage.
Patients randomised to the lenalidomide/low dose dexamethasone arm received lenalidomide 25 mg/day, days 1 to 21 every 28 days plus low dose dexamethasone - 40 mg/day on days 1, 8, 15, and 22 every 28 days.
• Alt sundhedspersonale, som har til hensigt at ordinere (og udlevere) Lenalidomide Accord, modtager en informationspakke til læger, inden produktet lanceres på markedet (og hvor det er hensigtsmæssigt og med samtykke fra den relevante nationale myndighed, inden udleveringen).
Prior to prescribing (and where appropriate, and in agreement with the National Competent Authority, prior to dispensing) all healthcare professionals who intend to prescribe (and dispense) Lenalidomide Accord are provided with a physician information pack containing the following:
Dosisniveau -2
Dose level -2
• Sæt med oplysningsmateriale til sundhedspersonale
• Educational Health Care Professional's kit
Episoder af grad 4 febril neutropeni blev observeret mindre hyppigt (0,6 % hos patienter, som blev behandlet med lenalidomid/dexamethason, sammenlignet med 0,0 % hos patienter, som blev behandlet med placebo/dexamethason).
Grade 4 febrile neutropenia episodes were observed infrequently (0.6% in lenalidomide/dexamethasone-treated patients compared to 0.0% in placebo/dexamethasone treated patients).
Nyligt diagnosticeret myelomatose: patienter, der har gennemgået ASCT og er i vedligeholdelsesbehandling med lenalidomid
Newly diagnosed multiple myeloma: patients who have undergone ASCT treated with lenalidomide maintenance
Episoder med grad 4 febril neutropeni blev ikke observeret hyppigt (1,7 % hos patienter i behandling med MPR+R/MPR+p, sammenlignet med 0,0 % hos patienter i behandling med MPp+p.
Grade 4 febrile neutropenia episodes were observed infrequently (1.7% in MPR+R/MPR+p treated patients compared to 0.0 % in MPp+p treated patients; see section 4.8).
Tid til progression, median [95 %konfidensinterval], uger p < 0,001
Time to progression Median [95% CI], weeks
Falder til < 30 x 109/l
Fall to < 30 x 109/L
Muskelsvaghed, knoglesmerter◊, smerter og ubehag i knogler, led, muskler og bindevæv (herunder rygsmerter◊)
Muscular weakness, Bone pain◊, Musculoskeletal and connective tissue pain and discomfort (including back pain◊)
Hæmolyse, autoimmun hæmolytisk anæmi, hæmolytisk anæmi
Haemolysis, Autoimmune haemolytic anaemia, Haemolytic anaemia
Kombinationen af lenalidomid og dexamethason er forbundet med en øget risiko for venøs tromboemboli (hovedsageligt dyb venetrombose og lungeemboli ) og blev observeret i mindre grad med lenalidomid i kombination med melphalan og prednison.
In patients with multiple myeloma, the combination of lenalidomide with dexamethasone is associated with an increased risk of venous thromboembolism (predominantly deep vein thrombosis and pulmonary embolism) and was seen to a lesser extent with lenalidomide in combination with melphalan and prednisone.
Kombinationen af lenalidomid og melphalan og prednison hos nydiagnosticerede patienter med myelomatose er forbundet med en større hyppighed af grad 4 neutropeni (34,1 % med MPR+R/MPR+p) sammenlignet med ed MPp+p (7,8 %).
The combination of lenalidomide with melphalan and prednisone in newly diagnosed multiple myeloma patients is associated with a higher frequency of grade 4 neutropenia (34.1% in MPR+R/MPR+p) compared with MPp+p (7.8%).
Hver kapsel indeholder 20 mg lenalidomid.
Each capsule contains 20 mg of lenalidomide.
• Tab af appetit
• Loss of vision
Grad 4 neutropeni blev observeret i lenalidomidarmene i kombination med lavdosis dexamethason i mindre grad end i den sammenlignende arm (8,5 % i Rd [kontinuerlig behandling] og Rd18 [behandling i 18 4-ugers cyklusser], sammenlignet med 15 % i armen med melphalan/prednison/thalidomid, se pkt.
• Newly diagnosed multiple myeloma: patients who are not eligible for transplant treated with lenalidomide in combination with low dose dexamethasone Grade 4 neutropenia was observed in the lenalidomide arms in combination with low dose dexamethasone to a lesser extent than in the comparator arm (8.5% in the Rd [continuous treatment] and Rd18 [treatment for 18 four-week cycles] compared with 15% in the melphalan/prednisone/thalidomide arm, see section 4.8).
Vender tilbage til ≥ 30 x 109/l
Return to ≥ 30 x 109/L
Meget almindelig Muskelspasmer, knoglesmerter◊, smerter og ubehag i knogler, led, muskler og bindevæv (herunder rygsmerter◊), artralgi◊
Muscle spasms, Bone pain◊, Musculoskeletal and connective tissue pain and discomfort (including back pain◊), Arthralgia◊
Dosisniveau -3
Dose level -3
Samlet set blev grad 4 neutropeni observeret med en højere frekvens i armene med lenalidomidvedligeholdelsesbehandling sammenlignet med armene med placebo-vedligeholdelsesbehandling i de 2 studier, der evaluerede lenalidomid-vedligeholdelsesbehandling hos NDMM-patienter, der har gennemgået ASCT (32,1% vs 26,7% [16,1% vs 1,8% efter påbegyndelse af vedligeholdelsesbehandling] i CALGB 100104 og 16,4% vs 0,7% i IFM 2005-02].
Overall, grade 4 neutropenia was observed at a higher frequency in the lenalidomide maintenance arms compared to the placebo maintenance arms in the 2 studies evaluating lenalidomide maintenance in NDMM patients who have undergone ASCT (32.1% vs 26.7% [16.1% vs 1.8% after the start of maintenance treatment] in CALGB 100104 and 16.4% vs 0.7% in IFM 2005-02, respectively).
Genoptag lenalidomid ved startdosis én gang dagligt
Resume lenalidomide at starting dose once daily
Der er sjældne rapporter om TLS hos MM-patienter i behandling med lenalidomid og ingen rapporter fra MDSpatienter i behandling med lenalidomid.
There have been rare reports of TLS in patients with MM treated with lenalidomide.
Behandling med lenalidomid må ikke startes ved ANC < 1,0 x 109/´l og/eller trombocyttal < 75 x 109/l eller, afhængigt af infiltrationen af plasmaceller i knoglemarven, trombocyttal < 30 x 109/l.
Lenalidomide treatment must not be started if the ANC < 1.0 x 109/L, and/or platelet counts < 75 x 109/L or, dependent on bone marrow infiltration by plasma cells, platelet counts < 30 x 109/L.
Nyrefunktion (kreatininclearance)
Renal function (CLcr)
Lenalidomide Accord 2,5 mg hårde kapsler Lenalidomide Accord 5 mg hårde kapsler Lenalidomide Accord 7,5 mg hårde kapsler Lenalidomide Accord 10 mg hårde kapsler Lenalidomide Accord 15 mg hårde kapsler Lenalidomide Accord 20 mg hårde kapsler Lenalidomide Accord 25 mg hårde kapsler
Lenalidomide Accord 2.5 mg hard capsules Lenalidomide Accord 5 mg hard capsules Lenalidomide Accord 7.5 mg hard capsules Lenalidomide Accord 10 mg hard capsules Lenalidomide Accord 15 mg hard capsules Lenalidomide Accord 20 mg hard capsules Lenalidomide Accord 25 mg hard capsules
Lenalidomids sikkerhed og virkning blev vurderet i et fase III, multicenter, randomiseret, open-label, studie (MM-020) med tre arme hos patienter, der var mindst 65 år eller ældre eller, hvis de var yngre end 65 år, ikke var kandidater til stamcelletransplantation, da de afslog at gennemgå en stamcelletransplantation, eller stamcelletransplantationen ikke var tilgængelig for patienten på grund af omkostninger eller andre årsager.
The safety and efficacy of lenalidomide was assessed in a phase III, multicenter, randomised, openlabel, 3-arm study (MM-020) of patients who were at least 65 years of age or older or, if younger than 65 years of age, were not candidates for stem cell transplantation because they declined to undergo stem cell transplantation or stem cell transplantation is not available to the patient due to cost or other reason.The study (MM-020) compared lenalidomide and dexamethasone (Rd) given for 2 different durations of time (i.e., until progressive disease [Arm Rd] or for up to eighteen 28-day cycles [72 weeks, Arm Rd18]) to melphalan, prednisone and thalidomide (MPT) for a maximum of twelve 42-day cycles (72 weeks).
Meget almindelig Neutropeni^,◊, febril neutropeni^,◊, trombocytopeni^,◊,
Very Common Neutropenia^,◊, Thrombocytopenia^,◊,
Kombination af lenalidomid og dexamethason hos patienter med myelomatose er forbundet med en højere forekomst af grad 4-neutropeni (5,1 % hos patienter, som blev behandlet med lenalidomid/dexamethason, sammenlignet med 0,6 % hos patienter, som blev behandlet med placebo/dexamethason).
The combination of lenalidomide with dexamethasone in multiple myeloma patients is associated with a higher incidence of grade 4 neutropenia (5.1% in lenalidomide/dexamethasone-treated patients compared with 0.6% in placebo/dexamethasone-treated patients).
• Kvinden forstår nødvendigheden af og accepterer at få foretaget graviditetstest hver 4. uge,
• She understands the need and accepts to undergo pregnancy testing every 4 weeks except in case of confirmed tubal sterilisation
Psykiske forstyrrelser Meget almindelig Depression, insomni
Very Common Depression, Insomnia Uncommon Loss of libido
Grad 3 og 4 trombocytopeni blev observeret med en højere forekomst i armene med lenalidomidvedligeholdelsesbehandling sammenlignet med armene med placebo-vedligeholdelsesbehandling i studier, der evaluerede lenalidomid-vedligeholdelsesbehandling hos NDMM-patienter, der havde gennemgået ASCT (37,5 % vs 30,3 % [17,9% vs 4,1% efter påbegyndelse af vedligeholdelsesbehandling] i CALGB 100104 og 13,0 % vs 2,9 % i IFM 2005-02).
Grade 3 or 4 thrombocytopenia was observed at a higher frequency in the lenalidomide maintenance arms compared to the placebo maintenance arms in studies evaluating lenalidomide maintenance in NDMM patients who have undergone ASCT (37.5% vs 30.3% [17.9% vs 4.1% after the start of maintenance treatment] in CALGB 100104 and 13.0% vs 2.9% in IFM 2005-02, respectively).
Kombinationen af lenalidomid sammen med melphalan og prednison i kliniske studier hos patienter med nydiagnosticeret myelomatose er forbundet med en større forekomst af grad 4 neutropeni (34,1 % i armen med melphalan, prednison og lenalidomid, efterfulgt af lenalidomid [MPR+R] og melphalan, prednison og lenalidomid, efterfulgt af patienter i behandling med placebo [MPR+p], sammenlignet med 7,8 % hos patienter i behandling med MPp+p.
• Newly diagnosed multiple myeloma: patients who are not eligible for transplant treated with lenalidomide in combination with melphalan and prednisone The combination of lenalidomide with melphalan and prednisone in clinical trials of newly diagnosed multiple myeloma patients is associated with a higher incidence of grade 4 neutropenia (34.1% in melphalan, prednisone and lenalidomide arm followed by lenalidomide [MPR+R] and melphalan, prednisone and lenalidomide followed by placebo [MPR+p] treated patients compared with 7.8% in MPp+p-treated patients; see section 4.8).
), måneder: alle overlevende patienter
Medianf (min, max), months: all surviving patients
Grad 4 febril neutropeni blev rapporteret med sammenlignelige hyppigheder i armene med lenalidomid-vedligeholdelsesbehandling og placebo-vedligeholdelsesbehandling i de to studier (0,4 % vs 0,5 % [0,4% vs 0,5% efter påbegyndelse af vedligeholdelsesbehandling] i CALGB 100104 og 0,3 % vs 0 % i IFM 2005-02).
Grade 4 febrile neutropenia was reported at similar frequencies in the lenalidomide maintenance arms compared to placebo maintenance arms in both studies (0.4% vs 0.5% [0.4% vs 0.5% after the start of maintenance treatment] in CALGB 100104 and 0.3% vs 0% in IFM 2005-02, respectively).
Lenalidomid-behandlingen må ikke startes, hvis ANC er < 1,5 x 109/l, og/eller trombocyttallet er < 75 x 109/l.
Lenalidomide treatment must not be started if the ANC is < 1.5 x 109/L, and/or platelet counts are < 75 x 109/L.
Sort jernoxid (E172) Titandioxid (E171)
Iron oxide black (E172) Titanium dioxide (E171)
Hver kapsel indeholder 7,5 mg lenalidomid.
Each capsule contains 7.5 mg of lenalidomide.
• Hævelse af led
• Weight loss
Det øger føtal hæmoglobin-produktion af CD34+-hæmatopoietiske stamceller og hæmmer monocytters produktion af pro-inflammatoriske cytokiner (f.eks. TNF-α og IL-6).
Specifically, lenalidomide inhibits proliferation of certain haematopoietic tumour cells (including MM plasma tumour cells and those with deletions of chromosome 5), enhances T cell- and Natural Killer (NK) cell-mediated immunity and increases the number of NK T cells, inhibits angiogenesis by blocking the migration and adhesion of endothelial cells and the formation of microvessels, augments foetal haemoglobin production by CD34+ haematopoietic stem cells, and inhibits production of pro-inflammatory cytokines (e.g., TNF-αand IL-6) by monocytes.
• Smerter i brystet, der spreder sig ud til arme, hals, kæbe, ryg eller mave, en følelse af at være svedig og kortåndet, kvalme eller opkastning (hvilket kan være symptomer på hjerteanfald/myokardieinfarkt)
• Chest pain spreading to the arms, neck, jaw, back or stomach, feeling sweaty and breathless,
Myokardieinfarkt (herunder akut)^,◊, atrieflimren◊, kongestiv hjerteinsufficiens◊, takykardi, hjerteinsufficiens◊,
Myocardial infarction (including acute)^,◊, Atrial fibrillation◊,
Først falder til < 25 x 109/l
First fall to < 25 x 109/L
Patienter med sværere grader af nedsat nyrefunktion kan i højere grad have en reduceret tolerance over for behandlingen (se pkt.
Lenalidomide is primarily excreted by the kidney; patients with greater degrees of renal impairment can have impaired treatment tolerance (see section 4.4).
benytte kondom under hele behandlingen, under dosisafbrydelse og i 1 uge efter behandlingsophør, hvis deres partner er gravid eller i den fertile alder og ikke bruger kontraception.
As a precaution, and taking into account special populations with prolonged elimination time such as renal impairment, all male patients taking lenalidomide should use condoms throughout treatment duration, during dose interruption and for 1 week after cessation of treatment if their partner is pregnant or of childbearing potential and has no contraception.
Hos patienter med myelomatose var behandling med lenalidomid-monoterapi forbundet med en lavere risiko for venøs tromboemboli (hovedsageligt dyb venetrombose og lungeemboli) end hos patienter med myelomatose, som blev behandlet med lenalidomid i kombinationsbehandling (se pkt.
In patients with multiple myeloma, , treatment with lenalidomide monotherapy was associated with a lower risk of venous thromboembolism (predominantly deep vein thrombosis and pulmonary embolism) than in patients with multiple myeloma treated with lenalidomide in combination therapy (see sections 4.5 and 4.8).
Fordeling (14C)-lenalidomids binding til plasmaproteiner in vitro var lav med gennemsnitlig plasmaproteinbinding på 23 % og 29 % hos henholdsvis patienter med myelomatose og raske forsøgspersoner.
Distribution In vitro (14C)-lenalidomide binding to plasma proteins was low with mean plasma protein binding at
Patienter med nydiagnosticeret myelomatose, som ikke er egnede til transplantation, og som er i behandling med lenalidomid i kombination med lavdosis dexamethason
Newly diagnosed multiple myeloma: patients who are not eligible for transplant treated with lenalidomide in combination with low dose dexamethasone
Lenalidomide Accord 5 mg og Lenalidomide Accord 25 mg hårde kapsler
Lenalidomide Accord 5 mg and Lenalidomide Accord 25 mg hard capsules Gelatin
• Nyreproblemer
• Kidney problems
Når trombocytter
When platelets
Den mediane samlede PFS2 var 69,9 måneder (95% CI 58,1-80,0) i lenalidomid-armen versus 58,4 måneder (95% CI 51,1-65,0) i placebo-armen.
The median overall PFS2 was 69.9 months (95% CI 58.1, 80.0) in the lenalidomide arm versus 58.4 months (95% CI 51.1, 65.0) in the placebo arm. For OS, the observed HR was 0.90: (95% CI 0.72, 1.13; p = 0.355) for lenalidomide versus placebo.
Mediana PFS2-tid, måneder (95% CI)b HR [95% CI]c ; p-værdid
Mediana PFS2 time, months (95% CI) b HR [95% CI]c ; p-valued
Kombinationen af lenalidomid og lavdosis dexamethason hos nydiagnosticerede patienter med myelomatose er forbundet med en lavere hyppighed af grad 3 og 4 neutropeni (8,1 % med Rd og Rd18), sammenlignet med MPT (11 %).
The combination of lenalidomide with low dose dexamethasone in newly diagnosed multiple myeloma patients is associated with a lower frequency of grade 3 and 4 thrombocytopenia (8.1% in Rd and Rd18) compared with MPT (11%).
Lenalidomide Accord 7,5 mg hårde kapsler Hver hård kapsel indeholder 7,5 mg lenalidomid.
Lenalidomide Accord 7.5 mg hard capsules Each hard capsule contains 7.5 mg of lenalidomide.
Progressionsfri overlevelse, median [95 %konfidensinterval], uger p < 0,001
Progression free survival Median [95% CI], weeks
Nydiagnosticeret myelomatose hos patienter, der ikke er egnede til transplantation, og som er i behandling med lenalidomid i kombination med melphalan og prednison.
Newly diagnosed multiple myeloma: patients who are not eligible for transplant treated with lenalidomide in combination with melphalan and prednisone